title: [Oncolytic virotherapy: new strategies in oncology].
abstract: The introduction of new therapeutical approaches to the medical practice has never been an easy task. On the one hand, modern therapies have to fulfil the strict requirements of the industry, on the other, patients and therapists have usually high expectations towards them. Thus, the public's initial euphoric emotions can quickly turn into pessimism following the experience of the first complications and difficulties of the new therapeutic method. Regarding oncolytic virotherapy, the emerging troubles and the lack of complete success upon the first clinical trials also led to the rejection of this promising new approach to the treatment of cancer. In the last few decades, however, due to the advances in molecular and cell biology, oncolytic virotherapy has been put in the lime-light again, and some of the newly developed virotherapeutic agents have been tested in various clinical trials all around the world. This review focuses on the current situation of the field and summarizes the available results.
authors.affiliation: Pécsi Tudományegyetem, Altalános Orvostudományi Kar, Orvosi Biológiai Intézet, Pécs Szigeti u. 12. 7624. zsolt.fabian@aok.pte.hu
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Fábián
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics; D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000821:virology; D009522:Newcastle disease virus / Q000235:genetics; D050130:Oncolytic Virotherapy / Q000379:methods; D050504:Oncolytic Viruses / Q000235:genetics*; D017955:Poliovirus / Q000235:genetics; D012087:Reoviridae / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics; D014412:Tumor Virus Infections / Q000150:complications* / Q000821:virology; D014616:Vaccinia virus / Q000235:genetics